University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still.
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
Salmonella Typhi bacteria can invade the intestines and blood and lead to a disease called typhoid fever \u2013 a disease that affects around 11 million people each year globally.
Drs Samantha Vanderslott and Claas Kirchhelle introduce their typhoid history research and 'Alice in Typhoidland' public engagement project. This work delves into the history of typhoid in Oxford and highlights why typhoid is still a major global health problem needing both water, sanitation, and hygiene (WASH) interventions alongside vaccines.
There are between 11 and 27 million estimated cases of enteric fever worldwide every year, and 75,000\u2013220,000 deaths. Could vaccination stop the spread of these diesases in the environment?
Dr Matthew Snape leads a study investigating if giving small amounts of oral insulin to babies can prevent type 1 diabetes, thus allowing mothers to protect their children from injecting insulin.
The National Health Service named Oxford Vaccine Group\u2019s Meningitis B vaccination programme one of the 70 most transformative discoveries over the past 70 years.
On November 20, 2017, the Typhoid Vaccine Acceleration Consortium (TyVAC) vaccinated the first of 20,000 children against typhoid, successfully launching a study to assess the impact of typhoid conjugate vaccines (TCVs) in preventing typhoid among children in Nepal.
Researchers are working with schools around the county to find 24,000 volunteers aged 16 to 18 years to take part in the Be on the TEAM (Teenagers Against Meningitis) trial, led by the Oxford Vaccine Group at the Oxford University's Paediatrics Department with funding and support from the National Institute for Health Research (NIHR).
The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against \u2018Meningitis B\u2019 could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom. Teenagers at participating schools are being asked to take part by local research teams involved.
Mildred Iro, a Paediatric Research Fellow working with the Oxford Vaccine Group, won the Lorber Prize for the best paediatric publication of 2017 for her work on childhood encephalitis admissions.
A new vaccine that could prevent up to nine-in-10 cases of typhoid fever has been recommended by the World Health Organization. By James Gallagher, Health and science reporter, BBC News website
The Oxford Safer Pregnancy Alliance [OSPREA] and the Oxford Vaccine Group [OVG] have recently undertaken a successful recruitment drive for a study of maternal immunisation to prevent infant Respiratory Syncytial Virus [RSV] infection.
Hannah Robinson and Sarah Loving from the Department of Paediatrics were recognised in the annual awards hosted by the Thames Valley Clinical Research Network
Respiratory Syncytial Virus (RSV) is one of the most common reasons for young infants to be admitted to hospital, and globally is second only to malaria as a cause of death in infants between 1 and 12 months of age. In the UK it mostly occurs from October to February, causing a wave of infections that stretch the capacity of children\u2019s wards to their limits.
![\"\"](\"https://www.ovg.ox.ac.uk/news/oxford-covid-19-vaccine-programme-opens-for-clinical-trial-recruitment/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n